317 related articles for article (PubMed ID: 9395151)
1. Citalopram in the treatment of obsessive-compulsive disorder: an open pilot study.
Koponen H; Lepola U; Leinonen E; Jokinen R; Penttinen J; Turtonen J
Acta Psychiatr Scand; 1997 Nov; 96(5):343-6. PubMed ID: 9395151
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study.
Mundo E; Bianchi L; Bellodi L
J Clin Psychopharmacol; 1997 Aug; 17(4):267-71. PubMed ID: 9241005
[TBL] [Abstract][Full Text] [Related]
3. Citalopram in refractory obsessive-compulsive disorder: an open study.
Marazziti D; Dell'Osso L; Gemignani A; Ciapparelli A; Presta S; Nasso ED; Pfanner C; Cassano GB
Int Clin Psychopharmacol; 2001 Jul; 16(4):215-9. PubMed ID: 11459335
[TBL] [Abstract][Full Text] [Related]
4. Citalopram for treatment-resistant obsessive-compulsive disorder.
Pallanti S; Quercioli L; Paiva RS; Koran LM
Eur Psychiatry; 1999 Apr; 14(2):101-6. PubMed ID: 10572334
[TBL] [Abstract][Full Text] [Related]
5. Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study.
Pallanti S; Quercioli L; Bruscoli M
J Clin Psychiatry; 2004 Oct; 65(10):1394-9. PubMed ID: 15491244
[TBL] [Abstract][Full Text] [Related]
6. Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial.
Pallanti S; Quercioli L; Koran LM
J Clin Psychiatry; 2002 Sep; 63(9):796-801. PubMed ID: 12363120
[TBL] [Abstract][Full Text] [Related]
7. Beyond depression: citalopram for obsessive-compulsive disorder.
Pato MT
Int Clin Psychopharmacol; 1999 May; 14 Suppl 2():S19-26. PubMed ID: 10471169
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy and tolerability of escitalopram in anxiety disorders: a review].
Pelissolo A
Encephale; 2008 Sep; 34(4):400-8. PubMed ID: 18922243
[TBL] [Abstract][Full Text] [Related]
9. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
Pigott TA; Seay SM
J Clin Psychiatry; 1999 Feb; 60(2):101-6. PubMed ID: 10084636
[TBL] [Abstract][Full Text] [Related]
10. Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors.
Maina G; Albert U; Salvi V; Bogetto F
J Clin Psychiatry; 2004 Oct; 65(10):1365-71. PubMed ID: 15491240
[TBL] [Abstract][Full Text] [Related]
11. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of long-term augmentation with citalopram to clomipramine in treatment-resistant OCD patients.
Marazziti D; Golia F; Consoli G; Presta S; Pfanner C; Carlini M; Mungai F; Catena Dell'osso M
CNS Spectr; 2008 Nov; 13(11):971-6. PubMed ID: 19037176
[TBL] [Abstract][Full Text] [Related]
13. Child and adolescent obsessive-compulsive disorder treated with citalopram: findings from an open trial of 23 cases.
Thomsen PH
J Child Adolesc Psychopharmacol; 1997; 7(3):157-66. PubMed ID: 9466233
[TBL] [Abstract][Full Text] [Related]
14. A randomized controlled clinical trial of citalopram versus fluoxetine in children and adolescents with obsessive-compulsive disorder (OCD).
Alaghband-Rad J; Hakimshooshtary M
Eur Child Adolesc Psychiatry; 2009 Mar; 18(3):131-5. PubMed ID: 19190958
[TBL] [Abstract][Full Text] [Related]
15. Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorder.
Landeros-Weisenberger A; Bloch MH; Kelmendi B; Wegner R; Nudel J; Dombrowski P; Pittenger C; Krystal JH; Goodman WK; Leckman JF; Coric V
J Affect Disord; 2010 Feb; 121(1-2):175-9. PubMed ID: 19577308
[TBL] [Abstract][Full Text] [Related]
16. Escitalopram in the treatment of patients with schizophrenia and obsessive-compulsive disorder: an open-label, prospective study.
Stryjer R; Dambinsky Y; Timinsky I; Green T; Kotler M; Weizman A; Spivak B
Int Clin Psychopharmacol; 2013 Mar; 28(2):96-8. PubMed ID: 23211492
[TBL] [Abstract][Full Text] [Related]
17. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators.
Zohar J; Judge R
Br J Psychiatry; 1996 Oct; 169(4):468-74. PubMed ID: 8894198
[TBL] [Abstract][Full Text] [Related]
18. Obsessive-compulsive disorder: an open-label pilot trial of escitalopram.
Galvão-de Almeida A; Quarantini LC; Góis CR; Santos-Jesus R; Miranda-Scippa AM; de Oliveira IR; da Silva Prado H; Leckman JF; Rosário MC
CNS Spectr; 2007 Jul; 12(7):519-24. PubMed ID: 17603402
[TBL] [Abstract][Full Text] [Related]
19. Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison.
Koran LM; McElroy SL; Davidson JR; Rasmussen SA; Hollander E; Jenike MA
J Clin Psychopharmacol; 1996 Apr; 16(2):121-9. PubMed ID: 8690827
[TBL] [Abstract][Full Text] [Related]
20. Response of symptom dimensions in obsessive-compulsive disorder to treatment with citalopram or placebo.
Stein DJ; Andersen EW; Overo KF
Braz J Psychiatry; 2007 Dec; 29(4):303-7. PubMed ID: 18200396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
